分组1: Bristol Myers Squibb - Bristol Myers Squibb offers an attractive dividend yield of 4.6% with a payout ratio of around 85%, indicating a balance of risk and reward for investors [4][6][12] - The company faces potential patent cliffs, with its cancer drugs Revlimid and Pomalyst facing generic competition in 2026, and cardiovascular drug Eliquis losing patent protections in 2028 [6][4] - Despite these challenges, Bristol Myers Squibb has been investing in its drug pipeline through acquisitions, suggesting a likelihood of sustaining its dividend [6][4] 分组2: Medtronic - Medtronic has a dividend yield of 2.9% and has experienced a slowdown in dividend growth, which has dropped from mid to high single digits to low single digits [8][11] - The company is undergoing a restructuring to refocus on growth, including exiting certain businesses and investing in new products, with a notable spinoff of its diabetes division planned [9][11] - Medtronic has increased its dividend for 48 consecutive years, indicating strong potential for future growth and a payout ratio of around 75%, positioning it well for long-term investors [11][12]

Core Viewpoint - Agios Pharmaceuticals has received FDA approval for mitapivat, a treatment for anemia in adults with alpha or beta thalassemia, which will be marketed as AQVESME in the United States [2]. Group 1: FDA Approval - The FDA has approved mitapivat for treating anemia in adults with alpha or beta thalassemia [2]. - The drug will be marketed under the brand name AQVESME in the United States [2]. Group 2: Investor Relations - Morgan Sanford, Vice President of Investor Relations, is leading the conference call to discuss the approval and its implications [2]. - The company has provided access to presentation slides on its website for investors [2].

| | | 12月22日，据NMPA官网显示，海南合瑞制药提交的4类仿制药布地奈德肠溶胶囊获批上市，斩获国内首仿，打破云顶新耀在igAN对因治疗市场的独占局 面，重塑该领域竞争格局。 截图来源：NMPA 布地奈德肠溶胶囊是一款布地奈德的创新口服靶向迟释制剂，用于治疗具有进展风险的原发性IgA肾病成人患者。作为全球首个IgA肾病的对因治疗药物， 布地奈德肠溶胶囊不仅填补了国内从疾病源头治疗IgA肾病的空白，更为患者提供了创新的治疗选择。 大涨1581%重磅品种，云顶新耀独占鳌头 布地奈德肠溶胶囊原研公司为Calliditas，作为重磅药物，2019年，云顶新耀从Calliditas公司引进了该产品在大中华地区和新加坡的商业化权益，2023年11 月21日在国内获批上市，商品名为耐赋康，用于治疗具有进展风险的原发性免疫球蛋白A（IgA）肾病成人患者，以降低蛋白尿水平。2025年1月1日起布地 奈德肠溶胶囊正式纳入医保报销。 | 药品名称 | 通用名 | 医保目录剂型 ( | 注册剂型 0 | 医保类别 | 医保编号 | 药品分类(功能) | 区域 | 增补情况 | | --- | --- | --- | --- ...

The S&P 500 hit a record high on Wednesday, with broad gains across sectors supporting the main indexes during a shortened Christmas Eve session. The benchmark S&P 500 touched an intraday record high of 6,921.42 points, surpassing its previous peak in October, as investors continued to bet on more interest rate cuts from the Federal Reserve next year following mixed economic data. The U.S. economy grew at its fastest pace in two years in the third quarter, government data showed on Tuesday, after the releas ...

Stocks stocks closed higher on Wednesday, as the Dow Industrials and S&P 500 registered record closing highs in a broad rally during a holiday-shortened session.The blue-chip Dow rose 288.75 points, or 0.60%, to 48,731.16. The S&P 500 gained 0.3% to end at 6,932.05 points, while the Nasdaq climbed 0.2%.Indexes have been climbing in recent days, buoyed in part by a rebound in AI-related names after last week’s selloff that was triggered by concerns about inflated valuations and high capital expenditures dent ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Johnson & Johnson.Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 11 trades.If we consider the specifics of each trade, it is accurate to state that 72% of the investors opened trades with bullish expectations and 0% with bearish.From the overall spotted trades, 4 are puts, for a total amount of $411,540 and 7, calls, for a total amount of $424,038.What's The Price Target?Analyzing the Volume and Open Inter ...

Company Overview - Agios Pharma has seen a stock return of -29% over the past year, underperforming the market by 47%, which supports a cautious investment stance [1] Leadership and Background - The company has a co-founder, Brendan, who has a Ph.D. in organic synthesis from Stanford University and has experience working with major pharmaceutical companies and biotech startups [1]

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Eagle Pharmaceuticals, Inc. which may affect shareholder rights [1] Group 1: Shareholder Rights and Legal Options - Long-term shareholders of Eagle stock may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2] - Shareholder involvement is crucial for improving company policies and practices, leading to enhanced shareholder value [3] Group 2: Legal Representation and Firm Background - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4]

Core Insights - Sanofi's new drug application (NDA) for tolebrutinib, a Bruton's tyrosine kinase (BTK) inhibitor for treating non-relapsing secondary progressive multiple sclerosis (nrSPMS), received a complete response letter (CRL) from the FDA [1] Regulatory Developments - The FDA's CRL for tolebrutinib was anticipated, as the review timeline had already been extended twice earlier this year [2] - The initial decision date of September 28, 2025, was pushed to December 28, 2025, due to Sanofi's submission of additional analyses deemed a major amendment [3] - Following the submission of an expanded access protocol at the FDA's request, the review date was revised again, with further guidance expected by the end of Q1 2026 [4] Market Performance - Over the past six months, Sanofi's shares have increased by 1.1%, while the industry has seen a rise of 20.4% [5] International Approvals - Tolebrutinib received provisional approval in the UAE for treating nrSPMS and slowing disability accumulation in adults [6] - A regulatory filing for a similar indication is currently under review in the European Union [6] Clinical Study Outcomes - The phase III PERCEUS study for tolebrutinib in primary progressive multiple sclerosis (PPMS) did not meet its primary endpoint [10] - Sanofi has decided not to pursue further development of tolebrutinib in PPMS, which represents 10% of the overall MS patient population [11] - In 2022, the FDA placed a partial clinical hold on phase III studies for tolebrutinib due to identified cases of drug-induced liver injury [11] Other Regulatory Approvals - The European Commission approved Wayrilz (rilzabrutinib) for immune thrombocytopenia (ITP) in adult patients refractory to other treatments [13] - The approval was based on data from the phase III LUNA 3 study, which met both primary and secondary endpoints [14]

Key Points The new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant. The positive update turns the company's fortunes around after a disappointing update earlier in the year. 10 stocks we like better than Agios Pharmaceuticals › Shares in Agios Pharmaceuticals (NASDAQ: AGIO) soared by more than 18% as of 11 a.m. today. The move follows the company's receipt of approval from the Food and Drug Administration (FDA) for AQVESME (mitapiv ...